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Kaposi’s sarcoma-associated herpesvirus (KSHV) is associated with multiple human malignancies, includ-
ing Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Following primary
infection, KSHV typically goes through a brief period of lytic replication prior to the establishment of latency.
Plasmacytoid dendritic cells (pDCs) are the major producers of type 1 interferon (IFN), primarily in response
to virus infection. Toll-like receptors (TLRs) are key components of the innate immune system, and they serve
as pathogen recognition receptors that stimulate the host antiviral response. pDCs express exclusively TLR7
and TLR9, and it is through these TLRs that the type 1 interferon response is activated in pDCs. Currently,
it is not known whether KSHV is recognized by pDCs and whether activation of pDCs occurs in response to
KSHV infection. We now report evidence that KSHV can infect human pDCs and that pDCs are activated upon
KSHV infection, as measured by upregulation of CD83 and CD86 and by IFN- secretion. We further show that
induction of IFN- occurs through activation of TLR9 signaling and that a TLR9 inhibitor diminishes the
production and secretion of IFN- by KSHV-infected pDCs.
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the eti-
ological agent of Kaposi’s sarcoma, primary effusion lym-
phoma (PEL), and multicentric Castleman’s disease (MCD)
(8, 9). KSHV, also known as human herpesvirus 8 (HHV-8), is
a gammaherpesvirus belonging to the Rhadinovirus genus. Like
other herpesviruses, KSHV can establish a lifelong infection in
the human host. KSHV exhibits two different phases in its life
cycle, a latent phase and a lytic phase. It persists in the host cell
as a viral nuclear episome during the latent phase. During the
lytic phase of its life cycle, it replicates its viral genome to
produce viral progeny. In most cell types, primary infection is
usually followed by lytic replication, but within 3 to 4 days
following primary infection, KSHV typically enters a latent
state (20). KSHV is tropic for many different cell types, includ-
ing endothelial cells, monocytes, B cells, dendritic cells (DCs),
and hematopoietic progenitor cells (5, 6, 27, 36). Several recent
studies have shed light on the requirements for KSHV infec-
tion of macrophages and dendritic cells. DC-SIGN was iden-
tified as the receptor for KSHV present on dendritic cells and
macrophages (30). Pretreating cells with an antibody against
DC-SIGN blocked KSHV infection of these cell types (30).
DC-SIGN was also identified as being critical for KSHV in-
fection of activated B cells isolated from blood and tonsils (30).
Infection of dendritic cells was subsequently shown to lead to
increases in several cytokines and chemokines, including the
following: interleukin-6 (IL-6), tumor necrosis factor alpha
(TNF-), macrophage inflammatory protein 1 (MIP-1), and
IL-12 p40, among others (30).
Toll-like receptors (TLRs) play a vital role in the innate
immune response to viral infection, recognizing specific pat-
terns on invading pathogens (3). Currently, 10 human TLRs
have been identified, and for 9 of these a well-defined function
has been established. A subset of the TLR family, including
TLRs 3, 7, 8, and 9, is expressed primarily in the endosomal
compartment of cells that express these proteins (1, 2). The
TLR expression profile is different depending on the cell type.
Specifically, human plasmacytoid DCs (pDCs) express only 2
of the 10 human TLRs, TLR7 and TLR9 (18). TLR7 has been
shown to recognize single-stranded RNA, while TLR9 recog-
nizes CpG DNA sequences (1, 4, 14). Both types of nucleic
acid are common by-products of viral infection. TLR7 and
TLR9 have both been shown to play key roles in activating the
innate immune response against invading viruses.
pDCs are a rare cell type in the blood, comprising approx-
imately 0.4% of the total peripheral blood mononuclear cell
(PBMC) population (24). pDCs are a subset of the profes-
sional antigen-presenting dendritic cell population; however,
the primary role of pDCs is to produce type 1 interferon (IFN)
in response to virus infection (21, 24). Both RNA and DNA
viruses have been shown to activate or stimulate pDCs, result-
ing in type 1 IFN production. These viruses include herpes
simplex viruses 1 (HSV-1) and 2 (HSV-2), Sendai virus, influ-
enza virus, human immunodeficiency virus (HIV), human cy-
tomegalovirus (HCMV), and Epstein-Barr virus (EBV) (10,
12, 15, 17, 25, 29, 32). Each of these viruses stimulate IFN
production through activation of the TLR pathway in pDCs.
There is also evidence that pDCs can play a helper role in
herpesvirus infection (34) and can be among the primary re-
sponders to herpesvirus infection. Intranasal inoculation of
mice with murine herpesvirus 68 (MHV-68) led to the recruit-
ment of pDCs to the lung and subsequently led to the activa-
tion of DCs, even in the absence of a type 1 IFN response,
suggesting that pDCs can activate additional immune effector
cells following herpesvirus infection. pDCs also produce IFN
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in response to synthetic oligonucleotide ligands, such as A-type
CpG oligonucleotides [those which contain a poly(G) tail]
(12). As mentioned above, pDCs express 2 of the 10 known
human TLRs, TLR7 and TLR9. Both TLR7 and TLR9 are
expressed in the endosome, a compartment in which virus
entry commonly takes place. Therefore, exposure of viral nu-
cleic acids within the endosome during primary infection
would likely lead to an immediate and strong induction of type
1 IFN. TLR7 and TLR9 have both been shown to play impor-
tant roles in the elicitation of the type 1 IFN response seen
after infection of pDCs. TLR9 recognizes HSV-2 (25), TLR7
recognizes HIV (26), and both TLR7 and -9 are involved in
recognition of EBV (29).
We previously reported that KSHV modulates the TLR
signaling pathway (13, 35). We found that KSHV activates
TLR3 upon primary infection of monocytes and that TLR7/8
stimulation of latent KSHV-infected B lymphocytes results in
viral reactivation (13, 35). Here we investigated whether
KSHV could activate and stimulate an IFN response from
human pDCs and whether TLR recognition/signaling was re-
quired for this response. Although we reported that TLR3 was
activated during primary infection of human monocytes, TLR3
is not thought to be expressed in pDCs (37). Hence, we queried
whether TLR7 and TLR9, the only two TLRs known to be
expressed in human pDCs, could recognize KSHV during pri-
mary infection. In addition, we wanted to determine if KSHV
could infect and replicate in pDCs, as shown for some viruses.
We report here that KSHV infection of pDCs leads to a strong
IFN- response and that this response requires infectious virus
particles and is due partly to activation of TLR9. We also
report that the cell surface markers CD83 and CD86 are up-
regulated in pDCs following KSHV infection. Finally, we con-
firmed the presence of both lytic and latent KSHV gene tran-
scripts in pDCs.
MATERIALS AND METHODS
Cell culture. Purified pDCs were maintained in RPMI 1640 medium (Cellgro)
containing 10% human AB serum (Invitrogen), 1% penicillin-streptomycin (P-
S), and 10 ng/ml of IL-3 (PeproTech). Vero cells stably expressing KSHV-green
fluorescent protein (KSHV-GFP) were the kind gift of Jeff Vieira (33). They
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Cellgro)
containing 10% fetal bovine serum (FBS), 1% P-S, and 0.005 mg/ml of puromy-
cin (for selection). Both Vero cells and pDCs were grown at 37°C under 5% CO2.
Sf9 cells were maintained in Sf-900 serum-free medium containing amphotericin
B (0.25 g/ml) and P-S (0.1%). Sf9 cells were grown at 30°C in a monolayer.
Virus production and purification. Virus was produced as described previously
(35). In brief, baculovirus ORF50, a kind gift of Jeff Vieira (33), was amplified in
Sf9 cells for 72 h, after which the cell debris was pelleted and the supernatant
stored at 4°C. Vero cells stably expressing KSHV-green fluorescent protein were
then infected with baculovirus ORF50 in DMEM (without phenol red) contain-
ing 2% FBS, 1% P-S, and 2 mM sodium butyrate to allow reactivation of the
latent KSHV. After 72 h, the supernatant was harvested, cell debris pelleted, and
the supernatant filtered through a sterile 0.45-m filter. In order to concentrate
the virus, 30 ml of supernatant was layered over an 5-ml cushion of 20% sucrose
(optical grade; Sigma), and the virus was pelleted by ultracentrifugation in an
SW28 swinging-bucket rotor for 3 h at 4°C in a Beckman ultracentrifuge. The
supernatant was decanted, and the virus pellet was resuspended in sterile phos-
phate-buffered saline (PBS) in 1% of the original volume. The UV inactivation
of KSHV was measured as previously described (35).
Human plasmacytoid dendritic cell isolation and infection. Human pDCs
were isolated from buffy coats (Gulf Coast Labs) by use of a Diamond plasma-
cytoid dendritic cell isolation kit (Miltenyi Biotec) according to the manufactur-
er’s instructions. Following isolation, cells were stained with CD303 (BCDA-2)–
fluorescein isothiocyanate (FITC) and/or CD123-phycoerythrin (CD123-PE)
(both from Miltenyi Biotec) antibody according to the manufacturer’s protocol.
Flow cytometry was carried out on a MACSQuant analyzer (Miltenyi Biotec).
On average, we were able to obtain 95% to 98% purity throughout the course of
the experiments. pDC infections were carried out as follows. Freshly isolated
pDCs were counted and plated into either 96-well plates or 8-well coverslip-
bottom chamber slides (Lab-Tek) (for microscopy). On average, between 1  105
and 2  105 cells were incubated in RPMI plus 1% P-S and IL-3 (10 ng/ml), with
either 100 l of Dulbecco’s PBS (D-PBS) (mock) or 100 l of concentrated
KSHV (approximately 2  107 genomes/ml), for 1 h at 37°C. For most assays,
except the immunofluorescence assay, pDCs were infected with KSHV and
centrifuged for 30 min at 1,500 rpm at 30°C. After infection, human AB serum
was added to all wells (mock and infected) to the correct final concentration.
When investigating CD83 and CD86 activation by KSHV infection, IL-3 was not
added to the medium, as it has previously been shown to be necessary to drive
pDCs toward a dendritic cell morphology characterized by CD86 and CD83
upregulation (reviewed in reference 24). The medium was refreshed at either
16 h postinfection or 24 h postinfection. For all microscopy and flow cytometry
analyses, cells were harvested and used fresh. For RNA, DNA, or protein
analysis, cells were harvested and flash frozen prior to use. All supernatants were
flash frozen prior to analysis.
IFN- ELISA. An enzyme-linked immunosorbent assay (ELISA) specific for
IFN- (human origin; PBL Interferon Source) was used per the manufacturer’s
instructions to analyze the amount of IFN- secreted from KSHV-infected
pDCs. Briefly, standards and samples were added to precoated microtiter wells,
covered, and incubated for 1 h at room temperature. The plate was washed with
a diluted wash buffer concentrate, 100 l of diluted antibody concentrate was
added, and the plate was incubated for 1 h at room temperature. The plate was
then washed three times, followed by incubation with 100 l of diluted horse-
radish peroxidase (HRP) for 1 h at room temperature. Following HRP incuba-
tion, the plate was washed four times and then incubated with 100 l of tetra-
methylbenzidine (TMB) substrate for 15 min, uncovered and in the dark. After
15 min, 100 l of stop solution was added and the plate was analyzed on a
microplate reader to determine the absorbance at 450 nm. The standard (pro-
vided by the manufacturer) was plotted, and the concentration for each sample
was determined based on the standard curve.
Cytokine array analysis. A human cytokine antibody array (RayBiotech) was
used as described previously (35) to quantify the overall cytokine activation
pattern following KSHV infection of pDCs. The protocol was performed as
described by the manufacturer. Briefly, each array membrane was blocked and
then incubated overnight at 4°C with supernatant collected from either KSHV-
infected pDCs or mock-infected pDCs (diluted to the minimum volume specified
by the manufacturer). The arrays were then washed and incubated with biotin-
conjugated antibody solution, specific to each array, for 2 h at room temperature.
The membranes were washed again and then incubated with a horseradish
peroxidase-conjugated streptavidin solution for 2 h, followed by a wash step.
Arrays were then exposed to detection buffer for 2 min and exposed to X-ray
film. Quantitation of the individual dots was done using the ImageJ program.
TLR9 inhibition. The TLR9 inhibitor G-ODN was purchased from Invivogen.
G-ODN was resuspended in water per the manufacturer’s instructions, at a stock
concentration of 500 M. G-ODN was added to pDCs at a final concentration of
25 M or 40 M in serum-free medium. G-ODN was added simultaneously with
either KSHV or CpG DNA (ODN 2395) (Invivogen) per the manufacturer’s
instructions. CpG was used at 10 M (from a stock of 500 M) and served as a
positive control for IFN- induction.
Fluorescence microscopy. Confocal fluorescence microscopy was performed
on a Zeiss LSM5 Pa laser scanning microscope. pDCs were infected in 8-well
chamber slides as described above, and live cells were imaged at 24 and 48 h
postinfection in differential interference contrast (DIC) and FITC channels.
Flow cytometry. Flow cytometry was performed on a MACSQuant analyzer
(Miltenyi Biotec). To analyze the purity of isolated pDCs, freshly isolated cells
were stained with CD303 (BCDA-2–FITC) and/or CD123-PE for 10 to 20 min
on ice, washed with PBS, and fixed prior to analysis on the MACSQuant instru-
ment. For analysis of CD83 and CD86 upregulation, mock-infected and infected
pDCs were harvested, washed with D-PBS, and then stained with CD83-allo-
phycocyanin (CD83-APC) and CD86-APC (BD Pharmingen) on ice for 20 min.
The antibody was then washed out (three times) with PBS, and cells were fixed
in fluorescence-activated cell sorter (FACS)/fixing buffer (0.02% sodium azide,
1% paraformaldehyde in PBS) and analyzed for activation. Data were analyzed
using the Summit v4.3 program.
Viral transcription. In order to determine the amount of viral transcripts
present in infected cells, RNAs were isolated from infected pDCs by use of an
RNeasy Micro kit (Qiagen) per the manufacturer’s instructions and as previously
described (35). In order to generate cDNA, 10 l of RNA was reverse tran-
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scribed, using Moloney murine leukemia virus (MMLV) reverse transcriptase
(Invitrogen) and random hexamer primers (Invitrogen). Reverse transcription-
PCR (RT-PCR) was then performed, using the cDNA as a template and ORF57
primers (13) or ORF73 (LANA) primers (20) in a Sybr green PCR master mix
(Applied Biosystems). Primers for either glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) or -actin were used as controls. RT-PCRs were run on 1.5%
agarose gels.
RESULTS
Purification and infection of pDCs. We wanted to determine
whether pDCs were involved in the initial recognition of
KSHV following infection, so we investigated whether primary
KSHV infection could activate human pDCs. pDCs were iso-
lated from the blood of healthy human donors. Briefly, buffy
coats were centrifuged over Ficoll-Paque gradients to isolate
PBMCs. pDCs were first isolated via negative selection of the
PBMC fraction, followed by purification using positive selec-
tion with an anti-BDCA-4 antibody, as BCDA-4 is a unique
marker of pDCs. The isolated cells were subsequently stained
with anti-BDCA-2–FITC and/or anti-CD123–PE (Miltenyi
Biotec) antibody to assess the purity of the pDC population.
We typically obtained a 95 to 98% pure pDC population.
Figure 1A depicts the purity of a representative pDC sample,
as analyzed by flow cytometry using only anti-BDCA-2–FITC
antibody staining. Figure 1B shows the purity of a representa-
tive sample obtained using both anti-BDCA-2–FITC and anti-
CD123–PE antibody staining. The purified pDCs were then
subjected to KSHV infection, using recombinant GFP-KSHV
(rKSHV.219) (33).
KSHV infection leads to activation of pDC surface markers
CD86 and CD83. pDCs have previously been shown to elicit a
T-cell response to viral infection (7, 11). Both CD83 and CD86
are critical in T-cell-mediated immune responses (22, 28).
CD86 can facilitate the activation of T cells and, consequently,
the adaptive immune response. CD86 can bind to two different
FIG. 1. Purity of pDCs isolated from human blood. We show a representative data set on the purities we were able to achieve upon isolation
of pDCs from human donors. Purification was carried out as described in Materials and Methods, using magnetic bead-based separation. Purified
pDCs were stained with BDCA-2–FITC (CD303) either alone (A) or in combination with CD123-PE (B) to determine cell purity. Data analysis
was performed using Summit v4.3.
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receptors on the surfaces of T cells, namely, CD28 and
CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (22).
Binding of CD86 to CD28 on naïve T cells can lead to in-
creased IL-12 transcription and to upregulation of CD25,
pushing the cells into the cell cycle (22). Conversely, binding of
CD86 to CTLA-4 can result in inhibition of T-cell receptor and
CD28 signaling, resulting in shutdown of the T-cell response
(22). CD83 is known primarily for being a marker of matura-
tion of DCs (reviewed in reference 23).
In order to determine whether CD83 and CD86 were up-
regulated in pDCs following KSHV infection, we infected, on
average, between 1  105 and 2  105 freshly isolated pDCs
from different donors with concentrated KSHV (approxi-
mately 2  107 genomes/ml), as described in Materials and
FIG. 2. CD83 activation at 16 h in KSHV-infected pDCs. pDCs were isolated from four different donors, and cells were either mock infected
or infected with KSHV. Cells were harvested at 16 h postinfection and stained using an anti-CD83–APC antibody. Flow cytometry was performed
on a Miltenyi MACSQuant analyzer. The data were analyzed using Summit v4.3.
898 WEST ET AL. J. VIROL.
Methods. At 16 h postinfection, the cells were harvested,
washed, and stained with anti-CD86–APC or anti-CD83–APC
antibody. The stained cells were then fixed and analyzed by
flow cytometry. At 16 h post-KSHV infection, there was an
upregulation of both CD83 (Fig. 2) and CD86 (Fig. 3) in the
virus-infected pDCs compared to the mock-infected cells. For
each donor, KSHV infection upregulated the surface expres-
sion of CD83 and CD86, although the percent activation dif-
fered by donor. We observed an average increase (across 4
donors) in CD83 expression of 28.9-fold and an average in-
crease in CD86 expression of 22.2-fold in KSHV-infected
pDCs compared to mock-infected pDCs. We also analyzed
CD83 and CD86 expression following infection with UV-inac-
tivated KSHV (UV-KSHV) to determine whether infectious
FIG. 3. CD86 activation at 16 h in KSHV-infected pDCs. pDCs were isolated from four different donors. Cells were infected with KSHV or
mock infected. Cells were harvested at 16 h postinfection and stained using an anti-CD86–APC antibody. Flow cytometry was performed on a
Miltenyi MACSQuant analyzer. The data were analyzed using Summit v4.3.
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virus is required for the upregulation of these two costimula-
tory molecules. In Fig. 4, we show that pDCs infected with
UV-KSHV did not display increased levels of either CD83 or
CD86, indicating that infection with live virus is required for
upregulation of CD83 and CD86.
KSHV can enter plasmacytoid dendritic cells. In order to
corroborate these findings, we infected pDCs with GFP-ex-
pressing KSHV and monitored GFP expression by confocal
microscopy. The recombinant KSHV strain that we used for
infection expresses GFP under the control of a CMV promoter
(33). As shown in Fig. 5A, we found that a small percentage of
pDCs actively expressed GFP following infection with the re-
combinant virus, while no GFP expression was detected in the
mock-infected cells. We also monitored GFP expression by
flow cytometry at 16 h postinfection (Fig. 5B). We found that
approximately 23% of pDCs were GFP positive at 16 h postin-
fection. These data suggest that KSHV can actively infect
pDCs.
Viral gene transcription is detected in KSHV-infected pDCs.
We next investigated whether viral gene expression could be
detected in KSHV-infected pDCs. Freshly isolated pDCs were
infected as described above, and at 48 and 72 h postinfection,
the cells were harvested and washed. Total RNA was isolated
and reverse transcribed to cDNA as described in Materials and
Methods. RT-PCR was performed with primers specific for the
lytic early gene ORF57. As shown in Fig. 5C, we were able to
detect ORF57 gene products via RT-PCR at 48 h postinfec-
tion. This indicates that lytic viral transcripts are made in pDCs
following KSHV infection, which might represent abortive or
complete lytic replication. We also detected expression of the
LANA transcript at 72 h post-KSHV infection (Fig. 5D).
These data, combined with the observation of GFP expression
in virus-infected cells, suggest that pDCs can be infected by
KSHV and that both lytic and latent viral transcripts are made
following infection.
pDCs produce and secrete IFN- in response to KSHV
infection. The hallmark of pDC activation following viral in-
fection is increased production and secretion of IFN- (24).
We analyzed KSHV-infected pDCs for increased IFN- pro-
duction by ELISA (PBL Interferon Source). pDCs and super-
natants were harvested at various time points post-KSHV in-
fection, and the supernatants were analyzed for IFN- levels.
As shown in Fig. 6A, IFN- secretion from KSHV-infected
pDCs significantly increased at each time point compared to
mock-infected pDCs. Taken together with the CD83 and
CD86 activation described above, our data suggest that KSHV
can activate pDCs and stimulate the production of large
amounts of type 1 IFN.
In order to determine whether pDCs produced IFN in re-
sponse to live virus infection by KSHV or if the IFN response
was a result of surface exposure to KSHV proteins, we infected
pDCs with either live GFP-expressing KSHV or UV-inacti-
vated KSHV. Viral infections with UV-inactivated virus were
carried out side by side with live virus infections in pDCs
freshly isolated from human blood. As shown in Fig. 6B, we did
not observe the same induction of IFN- in the pDCs infected
with UV-inactivated KSHV as in those infected with live virus.
This indicates that the increased production of IFN-, as well
as upregulation of CD83 and CD86 on the pDC surface, is
dependent on uncoating of the virus in the endosome and/or
on productive KSHV infection.
FIG. 4. CD83 and CD86 activation 16 h after infection of pDCs with KSHV. Cells were either mock infected, infected with wild-type (WT)
KSHV, or infected with UV-inactivated KSHV (UV-KSHV). Cells were harvested at 16 h postinfection and stained with either CD83-APC or
CD86-APC antibody. Flow cytometry was performed on a Miltenyi MACSQuant analyzer. The data were analyzed using Summit v4.3.
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Cytokine secretion following KSHV infection. In order to
determine the profiles of any additional cytokines that were
induced following KSHV infection of pDCs, we analyzed su-
pernatants from mock-infected and KSHV-infected cells using
cytokine antibody arrays. We were able to identify several
proteins that were induced upon KSHV infection of pDCs.
Table 1 shows a list of the cytokines that were consistently
upregulated across 3 donors. IL-6, IL-8, and three members of
the CC family of chemokines, MIP-1, MIP-1, and macro-
phage-derived chemokine (MDC/CCL22), were all upregu-
lated in KSHV-infected pDCs from three different donors
compared to mock-infected pDCs. We did observe other up-
regulated cytokines, e.g., TNF-, in some of the donors, but
this was not consistent across all donors.
FIG. 5. KSHV infection of pDCs. (A) Mock- or KSHV-infected live pDCs were imaged using confocal microscopy to identify KSHV-infected
cells. Cells expressing GFP were detected only in KSHV-infected pDCs, whereas no GFP was detected in the mock-infected cells. Images were
taken on a Zeiss LSM5 Pa laser scanning microscope and processed using the Zeiss LSM Image browser. (B) Percent GFP expression in
mock-infected pDCs versus KSHV-infected pDCs at 16 h postinfection. Flow cytometry of mock- and KSHV-infected cells. (C) Orf57 transcription
in KSHV-infected pDCs. Cell pellets were processed for RNA and reverse transcribed to cDNA. RT-PCR was performed using primers for the
viral early lytic gene Orf57. KSHV Orf57 transcription was detected only in KSHV-infected cells, not in mock-infected cells. Controls included
RT-PCR of -actin transcript levels. RT, reverse transcription of the isolated RNA; RT, isolated RNA was added to the RT-PCR mix to serve
as a control for genomic DNA contamination; NT, no template was added to the RT-PCR mix to serve as a negative control for the primer sets.
(D) Orf73 transcription in KSHV-infected pDCs. Analysis was performed as described for panel B. Controls included RT-PCR of GAPDH
transcript levels.
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TLR9 inhibition blocks IFN- secretion following KSHV
infection. In order to determine a possible mechanism for pDC
activation and IFN- secretion upon KSHV infection, we
tested the ability of pDCs to respond to KSHV infection in the
presence of a TLR9 inhibitor, G-ODN. The inhibitory oligo-
nucleotide was added simultaneously with KSHV (as described
in Materials and Methods) or with CpG DNA, which served as
a positive control. Supernatants from infected pDCs were har-
vested at 16 h postinfection and were analyzed by ELISA for
IFN- secretion. As shown in Fig. 7A, the IFN- response in
the pDCs treated with CpG alone or virus alone was increased
significantly over that in mock-treated cells. However, in sam-
ples treated in combination with either KSHV and TLR9 in-
hibitor or CpG and TLR9 inhibitor, the IFN- response was
significantly inhibited (Fig. 7A). These data suggest that the
IFN- response of pDCs stimulated by KSHV infection is
mediated partly through TLR9. We also analyzed two addi-
tional donors for IFN- production at both 16 and 45 h post-
KSHV infection in the presence of the TLR9 inhibitor. As
shown in Fig. 7B, both donors showed significant inhibition of
IFN- secretion at both 16 and 45 h postinfection in the pres-
ence of the inhibitor.
In order to further confirm that infection of pDCs and the
subsequent activation of IFN- via TLR9 were specific to
live virus infection, not a result of contaminating DNA
present in the concentrated KSHV stock, purified and con-
centrated virus was treated with 0.1 U of DNase for 10 min
at 37°C prior to pDC infection. Following pDC infection
with DNase-treated virions, supernatants were collected at
16 and 45 h postinfection and analyzed for IFN- secretion
by ELISA. There was no difference in IFN- secretion levels
following infection of pDCs with DNase-treated KSHV or
untreated KSHV (Fig. 7C).
DISCUSSION
Virus infection almost always results in the production of
type 1 IFN, one of the primary defenses employed by the
innate immune system to control virus infection. Plasmacytoid
dendritic cells have been shown to be the major producers of
type 1 IFN in response to stimuli in the blood cell population,
indicating that they play a vital role in the host response to
infection. Interestingly, in patients with hyaline-vascular
Castleman’s disease, elevated levels of pDCs have been ob-
served; however, the significance of this finding is not currently
known (7). The role of pDCs in KSHV pathogenesis is unclear.
However, secretion of cytokines and chemokines from virus-
infected pDCs may play a role in T-cell recruitment and in
promoting T-cell survival, along with T-cell polarization and
production of IFN-. Recruitment of CD4 and CD8 T cells
to sites of infection is also a consequence of pDC infection/
activation and secretion of chemokines (for a review, see ref-
erence 31). In addition, due to the migratory nature of pDCs,
it is possible that infection of these cells may aid in the dis-
semination of KSHV throughout the body (16).
KSHV is known to establish a life-long latent infection in the
human host. Hence, KSHV is able to survive the host innate
TABLE 1. Fold increases in cytokines upregulated upon KSHV
infection compared to mock infection of human pDCs
Donor
Fold increase in cytokine
MDC MIP-1 MIP-1 IL-6 IL-8
1 1.34 3.27 3.98 2.99 2.43
2 1.40 1.71 1.16 3.43 1.59
3 1.57 2.45 2.86 2.07 2.87
FIG. 6. KSHV infection of pDCs induces secretion of IFN-.
(A) IFN- secretion was measured at different time points post-KSHV
infection. Supernatants from infected pDCs were collected at the in-
dicated times postinfection and analyzed for the presence of IFN- by
ELISA. Mock-infected pDCs were used as the control. (B) Isolated
pDCs were subjected to mock infection, WT KSHV infection, or in-
fection with UV-KSHV at the indicated time points. Supernatants
were analyzed for the presence of IFN- by ELISA.
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immune response mounted against it during primary infection.
We wanted to determine whether the primary blood cell type
responsible for type I IFN production, pDCs, were involved in
the initial recognition of KSHV during primary infection and
whether KSHV could infect or stimulate a response from hu-
man pDCs. Additionally, since pDCs are not known to express
TLR3, a TLR we previously reported as being important for
KSHV activation in human monocytes (35), we wanted to
determine if a different TLR was responsible for KSHV rec-
ognition in pDCs, since pDCs express exclusively TLR7 and
TLR9.
We found that KSHV can infect pDCs and that KSHV
transcripts can be detected at 48 and 72 h postinfection. Ad-
ditionally, we report that pDCs secrete significant amounts of
IFN- in response to KSHV infection. The levels of IFN- that
we observed were similar to those observed when pDCs are
infected with HCMV (32) and slightly higher, on average, than
the levels observed when pDCs are infected with EBV (29).
Following KSHV infection of pDCs, we also observed upregu-
lation of the costimulatory molecules CD83 and CD86. These
have been shown to be activated by other herpesviruses, in-
cluding HSV-1 and HCMV (19, 32). Intriguingly, one of the
downstream effects of CD86 activation is the binding of
CTLA-4, which can modulate host T-cell responses (22).
Downregulation of the host T-cell response would provide a
great advantage to KSHV during its mission to establish la-
tency and avoid detection by the adaptive immune response.
Thus, inhibition of the T-cell response would greatly increase
the chances of KSHV survival and persistence in the host.
It is currently not known whether KSHV can establish la-
tency in pDCs, since under most tissue culture conditions
pDCs exhibit a very short life span of a few days (reviewed in
reference 21). Additionally, these cells also display short life
spans in vivo (21). However, it is plausible that KSHV-infected
pDCs could serve as transmitters of virus to other cells, since
they migrate to lymphatic tissues such as the spleen, thymus,
and lymph nodes and also migrate to sites of local infection
throughout the host (21).
We found that TLR9 is the primary mediator of the IFN-
response following KSHV infection of pDCs. Pretreatment of
pDCs with a TLR9-inhibitory oligonucleotide blocked IFN-
production. We cannot rule out a contribution from TLR7
signaling to activation and IFN production by pDCs, as there
are no commercially available TLR7-specific antagonists.
However, based on the data in Fig. 7, we can conclude that
TLR9 is the primary responder to KSHV infection in pDCs,
since inhibition of TLR9 led to an average reduction of 86% in
IFN- secretion from KSHV-infected pDCs compared to that
from untreated pDCs.
In summary, we report that pDCs are activated by KSHV
infection and respond via upregulation of CD83 and CD86 and
secretion of IFN-. KSHV infection of pDCs results in activa-
tion of the TLR9 signaling pathway, leading to increased pro-
duction and secretion of IFN- from infected cells.
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FIG. 7. TLR9 inhibition blocks IFN- secretion following KSHV
infection. (A) pDCs were treated with a TLR9-inhibitory oligonucle-
otide (G-ODN) at a 25 M final concentration simultaneously with
either KSHV or 10 M CpG DNA (as a positive control). Infections
were carried out as described in Materials and Methods. Supernatants
were harvested at 16 h postinfection and were analyzed for IFN-
production by ELISA. IFN- secretion is shown for cells that were
either mock infected, infected with KSHV, or treated with CpG (TLR9
agonist) in the presence or absence of the TLR9 inhibitor G-ODN.
(B) pDCs were obtained from 2 different donors and were either mock
infected or infected with KSHV in the presence or absence of the
TLR9 inhibitor. IFN- secretion was measured at 16 and 45 h post-
KSHV infection. (C) DNase treatment of purified KSHV intact virions
does not reduce IFN- levels following infection. Purified KSHV was
treated for 10 min at 37°C with 0.1 U of DNase I. pDCs were infected
with either WT or DNase-treated KSHV, and supernatants were col-
lected and analyzed for the presence of IFN-.
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